Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations
An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the preferred first-line treatment of choice for patients with *EGFR*-mutated advanced non-small cell lung cancer (NSCLC), with gefitinib, erlotinib, afatinib, dacomitinib and osimertinib being commonly used in clinical pr...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2022-06-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2022.12.071 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the preferred first-line treatment of choice for patients with *EGFR*-mutated advanced non-small cell lung cancer (NSCLC), with gefitinib, erlotinib, afatinib, dacomitinib and osimertinib being commonly used in clinical practice. About 10–20% of patients with NSCLC patients harbor uncommon *EGFR* mutations with varying sensitivity to different EGFR-TKIs. This review presents an overview of the latest clinical data on the potential treatment strategies for NSCLC harboring uncommon *EGFR* mutations. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |